Kornimate/medical-research-clean huggingface dataset:
cgrp induced migraine attacks in patients with high and low genetic load

Conditions: Migraine Without Aura

Summary: the investigators hypothesized that migraine without patients with many genetic loci associated with migraine (high genetic load) would be more sensitive and get provoked more migraine attacks by calcitonin gene-related peptide (cgrp) compared to patients with few genetic loci associated with migraine (low genetic load).

migraine is a very prevalent neurological disorder with a strong genetic factor. the common forms of migraine have a multifactorial and polygenic pattern of inheritance and genetics research is crucial for a deeper understanding of migraine mechanisms. recently, 12 genetic loci have been identified to be associated with migraine with (ma) and without aura (ma) in four large genome-wide association studies (gwas). the functional consequences of these genetic loci in humans are yet unknown. calcitonin gene-related peptide (cgrp) is a neuropeptide which plays a crucial role in the pathophysiology of migraine and is present in migraine relevant structures. cgrp can induce migraine attacks in mo patients via an adenosine monophosphate (camp) dependent pathway and cgrp antagonism is efficient in the treatment of migraine attacks. also, a recent study has showed that intracellular accumulation of camp is crucial for the induction of migraine attacks. however, cgrp does not cause migraine attacks in familial hemiplegic migraine (fhm), an autosomal dominant subtype of ma. the phenotype of the migraine inducing effects of cgrp might therefore be linked to some of the 12 genetic susceptibility loci that have been identified. one of the genetic loci (rs13208321) is located in a gene (fhl5) that is associated with the regulation of camp-responsive elements.

Eligibility criteria:
inclusion criteria: - migraine without aura patients genotyped for the 12 newly idetified gene variants associated with migraine. exclusion criteria: * other primary headache * a history of cerebrovascular disease and other cns- disease * a history suggesting ischaemic heart disease * serious somatic and mental disease * hypo- or hypertension * abuse of alcohol or medicine (opioid analgesics). * pregnant or breastfeeding women.
are surgeons ready to get the covid-19 vaccine?

Conditions: Covid19

Summary: the covid-19 pandemic continues to rage and most of the world is facing a second wave with continuous lockdown and strict measures aiming to control it. while vaccination is on its way, and has even started in several countries, trust and acceptance remain a challenge for an effective vaccination strategy, especially with the increasing vaccination hesitance in recent years . it is important to understand the main concerns towards the covid-19 vaccine so they can be addressed in a constructive way - more specifically among health care professionals who are at the frontline of the pandemic. the aim of this study is to evaluate whether surgeons are ready for the covid-19 vaccine and to understand their main concerns towards the vaccine. in an objective to evaluate the attitude of doctors towards the covid vaccine and the effect of prolonged lockdown on their psychological burden, the investigators created an anonymous survey of 21 questions.


Eligibility criteria:
inclusion criteria: * physicians affiliated to belgian hospitals exclusion criteria: * none
stress response in emergency among physicians in helicopter and ambulance based emergency medical systems

Conditions: Hormone Disturbance; Stress Reaction; Stress Related Disorder

Summary: stress reactions in emergency physicians will be measures using cortol-awakening-reaction, heart-rate-variability and standardised stress questionnaires

in a field study with within-subject design, there will be conducted the hormonal and physiological stress strain of emergency physicians working in rescue helicopters or van on different days of service on different headquarters. the investigation of the parameter of stress will be conducted on two days of rescue service, on two days of clinical service and as a control on two days off. the quantification of the hormonal stress strain will be carried out with the cortisol awakening response, there will be conducted 3 saliva samples with identical interval after getting up within 30 minutes. while the labour time on the rescue service and on the clinical service and the whole day off, the heart rate variability will show the degree of physiological stress. this will be measured with a pulse-belt on the chest, which the participant will carry the whole day. in addition, participants will fill out a set of questionnaire on the first day of measurement.

Eligibility criteria:
inclusion criteria: * medical doctor working in rescue helicopter or van exclusion criteria: * metabolic disease * autoimmune disease * heart disease * blood disease * mental disease * endocrinologic disease * bmi\>30 * \>10 cigarettes/day * taking cortisone medication
dexmedetomidine in mechanically ventilated neonates with single-organ respiratory failure.

Conditions: Mechanically-ventilated Neonates With Single-organ Respiratory Failure

Summary: clinical experience with dexmedetomidine in the paediatric population is limited. critical illness can affect drug pharmacokinetics and -dynamics; the investigators cannot simply extrapolate adult data for use in children but the investigators are in need of data on pharmacokinetics and pharmacodynamics in every paediatric subpopulation.

currently, dexmedetomidine is approved by the united states food and drug administration (fda) for short-term analgosedation (\<24h) in mechanically-ventilated critical care adult patients and sedation of non-intubated adult patients prior to and/or during surgical and other procedures. trials are underway to investigate its pharmacokinetics, clinical efficacy and safety in long-term use. clinical experience with dexmedetomidine in the paediatric population is limited. moreover, during childhood many developmental changes take place with consequences on drug exposure and drug response. finally, critical illness itself can affect drug pharmacokinetics and -dynamics. therefore, the investigators cannot simply extrapolate adult data for use in children but the investigators are in need of data on pharmacokinetics and pharmacodynamics in every paediatric subpopulation.

Eligibility criteria:
inclusion criteria: * patient age less than 1 month (male/female) (step-down strategy for age) * first included patients (n=30): postmenstrual age \>= 34 weeks (near-term neonates) * following included patients (n=30) : postmenstrual age \>= 25 weeks and \< 34 weeks (preterm neonates) * patients with single-organ respiratory failure in need for analgosedation (guidance : comfort neo score \>14 or numeric rating scale (nrs) score pain (p)/comfort (c)\>4) * patients admitted to the neonatal intensive care unit * expected to require at least 20 hours of mechanical ventilation exclusion criteria: * patients with neurologic conditions that prohibit an evaluation of adequate analgosedation * no arterial catheter in place at inclusion * patients who have received another investigational drug within 30 days * patients on continuous infusion with neuromuscular blockers * patients with a life expectancy \<72 hours * patients with a known allergy to fentanyl * congenital or acquired heart block (grade 3) * sustained bradycardia * haemodynamically unstable patients (definition : mean arterial pressure (map) lower than : postmenstrual age (in weeks) - 5 millimeter hg, eventually under dopamine infusion max. 16 mcg/kilogram/minute and/or dobutamine infusion maximal 16 mcg/kilogram/minute) * patients with significant renal insufficiency (creatinine plasma level \>1.5 milligram/deciliter) * patients with significant hepatic insufficiency (as estimated by local investigators) * previous treatment with α2-adrenoreceptor agonist clonidine within 14 days * absence of parental consent

Keywords: neonates single organ respiratory failure
effects of isolated lumbar extension resistance training alone and in combination with general exercise and manual therapy

Conditions: Low Back Pain; Multifidus; Exercise Therapy; Diagnostic Imaging

Summary: this study examines effects of machine-based isolated lumbar extension resistance exercise (ilex) on paraspinal muscle morphology and function, as well as pain intensity, disability and quality of life in patients with chronic low back pain and radiculopathy related to specific spinal disorders. current guidelines emphasize the necessity of treating chronic low back pain with integrative, holistic approaches due to its multidimensional nature. at the same time, an increasing number of studies highlight the importance of restoring lumbar muscle function and morphology through targeted training. regarding ilex, existing studies already support its clinical value, however, the optimal integration of ilex with other therapeutic modalities remains unclear. two groups will be enrolled in an ilex protocol (16 weeks, 25 sessions), while one of the groups will additionally participate in general exercise and manual therapy. after completion of the main program, participants will be given different options to continue the exercise therapy with a reduced frequency (e.g., once per month). after six months, a follow-up assessment will be conducted with all participants to analyze long-term efficacy.


Eligibility criteria:
inclusion criteria: 1. chronic lbp for \> 3 months, defined as pain in the region between the lower ribs and gluteal folds, with or without leg pain 2. seeking care in the facility of the study 3. doctoral assessment indicating symptoms related to disc herniations/protrusions and other specific conditions 4. moderate pain levels at the time of doctoral assessment exclusion criteria: 1. acute low back pain (pain \< 3 months) 2. familiarity with the device (usage within the previous 12 months) 3. fractures
clinical trial of menu labeling

Conditions: Calorie Consumption

Summary: the current study sought to examine the effect of menu labeling on food ordering and food consumption, including the effect of displaying calories along with other nutrients, such as sodium, fat, and sugar, as well as in different formats, such as traffic lights. the investigators hypothesize significant differences in the calorie amount of menu selections and food consumption across experimental conditions. the investigators anticipate that calorie amounts will be significantly higher in the no calorie information) compared to each of the other 3 conditions, and significantly lower in the traffic light conditions compared to calories only condition. 2) individuals in condition 1 (no calorie information) will be significantly more likely to underestimate the calorie content of their meals compared to individuals in the intervention conditions.


Eligibility criteria:
inclusion criteria: * 18 years of age or older, * able to speak and read english exclusion criteria: - no food allergies to gluten or other grain products

Keywords: nutrition policy food labelling diet obesity health behavior
clinical study of taurine combined with neoadjuvant chemo-immunotherapy for treatment of locally advanced gastric cancer

Conditions: Gastric Cancer

Summary: this project aims to evaluate the efficacy and safety of oral taurine supplementation combined with pd-1 inhibitor (serplulimab) and chemotherapy in inducing systemic cd8+ t cell responses and achieving improved gastric cancer patient outcomes than with serplulimab and chemotherapy alone.


Eligibility criteria:
inclusion criteria: 1. age 18-75 years old, no gender limitation; 2. pathologically confirmed gastric or gastroesophageal junction adenocarcinoma with ctnm stage ii/iii，t≥3, n ≥0, m=0； 3. expected survival of ≥ 3 months; 4. the tumor specimens were pd-l1 positive (cps ≥ 1)； 5. there is a measurable lesion with the possibility of radical r0 resection after evaluation by doctors； 6. eastern cooperative oncology group (ecog) performance status score of 0 or 1; 7. patients informed about the purpose and course of the study and provided a written consent to participate. exclusion criteria: 1. use of taurine agent within 1 month prior to the first dose of study treatment and throughout the study; 2. patients with positive her-2； 3. patients with gastrointestinal obstruction or active bleeding in the gastrointestinal tract, as well as perforation and dysphagia; 4. patients with severe heart, lung, liver, kidney, endocrine, hematopoietic system or psychiatric diseases were considered not suitable for the study group; 5. human immunodeficiency virus (hiv) infection or known acquired immune deficiency syndrome (aids) or autoimmune disease or immunosuppressant use； 6. there are patients who may increase the risk of participating in the study and study medication, or other severe, acute and chronic diseases, and are not suitable for participating in the clinical study according to the judgment of the investigator.

Keywords: taurine neoadjuvant immunotherapy and chemotherapy
toronto bedside swallowing screening test (tor-bsst) - a bedside swallowing screening for stroke patients

Conditions: Cerebrovascular Accident; Deglutition Disorders

Summary: this research will assess the accuracy of the toronto bedside swallowing screening test (tor-bsst), a new dysphagia screening test for patients with stroke. the purpose of the tor-bsst is to predict the presence of dysphagia in stroke patients across their continuum of care in a simple and efficient manner. this initial research will assess the accuracy of the tor-bsst in the acute and rehabilitative settings using videofluoroscopy as the gold standard for comparison. the results from this research will also assess the stability of the tor-bsst across nursing, its primary user, and generate an estimate for the prevalence of dysphagia in adult stroke patients in the acute and rehabilitative settings. participants in this research will be 315 stroke patients from several teaching centres in ontario, namely 105 acute patients from the university health network, sunnybrook \& women's college health sciences centre, and hamilton general hospital, and 210 patients in the rehabilitation setting from the toronto rehabilitation institute and parkwood hospital, london. both the tor-bsst and videofluoroscopic assessment will be administered within 24 hours of each other and interpreted according to published preferred practice guidelines for dysphagia. this research will be the first to implement and assess a standardised method for screening for dysphagia in stroke patients across the continuum of stroke recovery.


Eligibility criteria:
inclusion criteria: * patients with a new diagnosis of brainstem or cerebellar stroke * patients with a new diagnosis of cortical stroke with nih stroke scale score of 4 or above exclusion criteria: * patients with a previous history of stroke with dysphagia * patients with a confirmed history of parkinson's, parkinsonian syndrome, als, msa, ms, dementia, or other neurodegenerative disease * patients with a history of cranial neurosurgery * patients with a known previous or current oropharyngeal dysphagia due to structural or neurological cause * patients with active copd or current pneumonia

Keywords: cerebrovascular accident deglutition disorders stroke dysphagia screening
a phase ii study of the effect of a low calorie diet on patients undergoing liver resection

Conditions: Nonalcoholic Fatty Liver Disease; Hepatic Steatosis; Steatohepatitis

Summary: the purpose of this study is to measure the effect of a short-term low calorie diet on patients with a body mass index (bmi) over 25 who are undergoing liver surgery.


Eligibility criteria:
inclusion criteria: * age 18 or greater * clinical indication for a therapeutic liver resection * bmi of 25 kg/m2 or greater * informed consent exclusion criteria: * inability to comply with the pre-op diet * patients who have lost 5% or more of their usual body weight over the preceding one month * female patients of childbearing age who have a positive pregnancy test
blinded resection in case of the pancreatic insulinoma

Conditions: Insulinoma; Pancreas

Summary: the blinded resection avoided in case of pancreatic insulinoma

despite of the technique and technology developement there are still a lot of troubles to verify small benign-looking pancreatic nets. it can be especially important in case of insulinoma. the organic hyperilsulinism and severe hypoglicemia causeb by the insulin/proinsulin - producing lesion can lead to severe complications and evem death. there are some cases of the blinded resections of the pancreas in patients with the "hidden" insulinoma when the tumor can't be revealed during the preoperative diagnostics and intraoperatively. unfortunately, blind resection do not solve the problem of the hypoglicemia but also cause the specific pancreatic complications.

Eligibility criteria:
inclusion criteria: the blinded resection of the insulinoma exclusion criteria: other tumors

Keywords: insulinoma hypoglicemia blind resection hidden insulinoma asvs
polysomnography study of mk-6096 in participants with primary insomnia (mk-6096-011)

Conditions: Primary Insomnia

Summary: this was a cross-over, polysomnography (psg) study to test the safety, tolerability and effectiveness of different doses of mk-6096 in the treatment of participants with primary insomnia. the primary efficacy hypothesis was that at least one dose of mk-6096 is superior to placebo in improving sleep efficiency (se) as measured by psg on night 1 and at the end of 4 weeks of treatment (week 4).


Eligibility criteria:
inclusion criteria: * participant is willing to stay overnight at a sleep laboratory on 6 separate nights and is willing to stay in bed for at least 8 hours each night while at the sleep laboratory * participant's regular bedtime is between 9 pm and 12 am (midnight) * participant is able to read and complete questionnaires and diaries * participant is willing to refrain from napping during the study exclusion criteria: * if female, participant is breast feeding, pregnant, or planning to become pregnant * participant is expecting to donate eggs or sperm during the study * participant has any history of a neurological disorder * participant has a history within the past 6 months of a cardiovascular disorder such as unstable angina, congestive heart failure or acute coronary syndrome. * participant has difficulty sleeping due to a medical condition * participant has donated blood products within the 8 weeks prior to the study * participant plans to travel across 3 or more time zones during the study * participant is currently participating or has participated in a study with an investigational compound or device within the last 30 days
mmr vaccination among hiv-infected adults

Conditions: HIV

Summary: this is a prevalence study of protective antibodies to measles, mumps, and rubella (mmr) in hiv-infected adults and hiv-uninfected controls. mmr vaccination were provided to both groups who had no protective antibodies to at least one of the three viruses.

from july to august 2011, 500 hiv-infected and 132 hiv-uninfected participants those met the eligibility criteria were enrolled and tested for protective antibodies to measles, mumps, and rubella. all participants who had no protective antibody to at least one of the three viruses were recruited to vaccinate for mmr vaccine. between june to september 2012, 249 hiv-infected and 46 hiv-uninfected adults were vaccinated. antibodies to mmr were measured at week 8-12, and week 48 after vaccination, which were completed in august 2013. the results were ready for analysis in march 2014.

Eligibility criteria:
inclusion criteria: for hiv-infected participants, inclusions criteria were 1. 20-59 years old, ability to provide informed consent 2. receiving cart 3. cd4 cell count ≥200 cell/mm3 within 6 months before enrollment 4. plasma hiv-1 rna \<50 copies/ml, and 5) ability to provide informed consent. exclusion criteria: for both groups 1. pregnancy or lactating 2. receiving cancer treatment, organ transplantation, ≥0.5 mg/kg/day of prednisolone or equivalent, or immunomodulating treatment 3. impaired renal function (creatinine clearance \<30 ml/min) 4. impaired liver function as defined by child-pugh c.

Keywords: mmr vaccination hiv serologic response
video assisted study of salbutamol response in viral wheezing

Conditions: Wheezing

Summary: the study is video assisted cross-over study evaluating the effect of inhaled salbutamol in wheeze in children 6-24 months old.

the object of the study is to evaluate the effect of inhaled salbutamol in wheeze in children 6-24 months old. in despite of the lack of evidence of salbutamol, it is considered the gold standard in acute wheezing. placebo-controlled study would be unethical so all participants are treated with salbutamol based on current guidelines. instead, participants serve as control subjects of their own which is executed by a type video assisted cross-over study. participants are filmed before and after the treatment. afterwards a panel of pediatricians not participating in the treatment of the participants independently evaluates the difficulty of the wheeze. videos are randomly arranged and members of the panel are blinded to the time point (before/after) of videos. in addition, collected videos are analyzed using machine vision. biosignals are collected from the videos and evaluated using algorithms in order to show that machine vision can be utilized to evaluate the difficulty of wheezing. the machine vision analysis is compared to the evaluation of the panel of pediatricians.

Eligibility criteria:
inclusion criteria: * wheezing * salbutamol-treatment in emergency department prescribed exclusion criteria: * need for immediate resuscitation * immediate transfer to icu * suspicion of pneumonia based on the auscultation finding * suspicion of airway foreign body
specific autoantibody testing in patients with interstitial lung disease

Conditions: Interstitial Lung Disease

Summary: the purpose of this study is to evaluate the clinical utility of specific autoantibody testing in unmasking an underlying connective tissue disorder in patients who present with interstitial lung disease and found to have weak positive ana (1:400 titre) with no overt connective tissue disease manifestations or borderline/negative ana with some clinical suggestion of connective tissue disease.

it has been well established that patients with connective tissue disease associated interstitial lung disease respond better to immunosuppressive therapy, and have a better outcome compared to patients with idiopathic interstitial pneumonias. this makes it imperative to identify this group of patients for management and prognostication. unfortunately some of these patients do not demonstrate overt clinical manifestations of connective tissue disease and our current available autoantibody screen does not detect all potential autoantibodies present. we would like to test for specific autoantibodies in this group of patients to evaluate its clinical utility in identifying covert connective tissue diseases associated with interstitial lung disease.

Eligibility criteria:
inclusion criteria: 1. patients 21 years old and older 2. patients with interstitial lung disease who have been found to have weak positive ana (1:400 titre) with no overt connective tissue disease manifestations or borderline/negative ana with some clinical suggestion of connective tissue disease will be offered specific autoantibody testing exclusion criteria: 1. inability and unwillingness to sign informed consent 2. patients who are pregnant or have underlying malignancy

Keywords: interstitial lung disease idiopathic pulmonary fibrosis